There is also therapeutic evidence in this regard, with studies claiming that treatment with NK-1R antagonists is beneficial in defending the integrality of the BBB and may slow the progression of certain neurodegenerative diseases or prevent some early neurodegenerative dysfunction [94]. Here, TACR1 is linked to neurodegenerative disease.